



FOI

Food and Drug Administration  
Rockville MD 20857

JAN 23 1997

**TRANSMITTED VIA FACSIMILE**

Kathleen J. Day  
Director, Labeling and Promotion  
Pharmacia and Upjohn Company  
7000 Portage Road  
Kalamazoo, MI 49001

**RE: NDA# 20-379**  
Caverject (alprostadil for injection)  
MACMIS ID #5041

Dear Ms. Day:

Reference is made to Pharmacia and Upjohn's December 31, 1996, FDA Form 2253 submissions consisting of eight journal advertisements and a business reply card for Caverject (alprostadil for injection). The Division of Drug Marketing, Advertising and Communications (DDMAC) has reviewed these materials and find them to be in violation of the Federal Food, Drug, and Cosmetic Act and the applicable regulations. Specifically, DDMAC has identified the following violations:

- **Placement and size of proprietary and established name**

Pursuant to the regulations, the established (generic) name is required to be placed in direct conjunction with the proprietary (brand) name in promotional labeling and advertising. However, DDMAC notes that the established name does not appear with the proprietary name at the first and most prominent mention of the proprietary name in each of these advertisements. Further, DDMAC finds that the established name is absent on the business reply card.

DDMAC recommends that Pharmacia and Upjohn immediately discontinue the use of these, and all other promotional materials for Caverject that contain the same or similar violations. Please respond to these comments in writing by February 3, 1997. This response should include a list of all violative promotional materials and Pharmacia and Upjohn's method for discontinuing their use.


Ms. Kathleen Day  
Pharmacia and Upjohn Company  
NDA 20-379

Page 2

If Pharmacia and Upjohn has any questions or comments, please contact the undersigned by facsimile at (301) 594-6771, or at the Food and Drug Administration, Division of Drug Marketing, Advertising and Communications, HFD-40, Rm 17B-20, 5600 Fishers Lane, Rockville, MD 20857. DDMAC reminds Pharmacia and Upjohn that only written communications are considered official.

In all future correspondence regarding this matter, please refer to MACMIS ID # 5041, in addition to the NDA number.

Sincerely,



Mark W. Askine, R.Ph.  
Regulatory Review officer  
Division of Drug Marketing,  
Advertising and Communications

Ms. Kathleen Day  
Pharmacia and Upjohn Company  
NDA 20-379

Page 3

File Name:cjectnov.let

Drafted: Askine	Date: 01/21/97
Comment: Fleischer	Date: 01/21/97
Revised: Askine	Date: 01/21/97
Concur: Drezin	Date: 01/22/97

CC:  
HFD-40/NDA # 20-379  
HFD-40/Chron/Askine/Palmer  
HFD-580/NDA 20-379

MACMIS ID # 5041

MACMIS Type Code: LETT  
MACMIS Action Code: VIOL

2253 ID#: 47950

Material ID#: All ID #'s listed

Due Date: February 3, 1997  
Close Out: NO

FOI Status: Releasable